Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia

The goal of this clinical trial is to learn if icosapent ethyl (Vascepa) works to lessen the amount of inflammation in adults diagnosed with Community-Acquired Pneumonia (CAP). The main question it aims to answer is: What is the effect of taking Vascepa on inflammation in the arteries in patients with CAP? Researchers will compare the drug Vascepa to a placebo (a look-alike submstance that contains no drug) to see if Vascepa works to reduce inflammation in patients with CAP. Participants wil: * take Vacscepa or a placebo twice a day for 6 months * Visit the clinic 3 times (baseline, 30 days, and 6 months) for checkups and tests

NCT Number	NCT06710080
Lead Sponsor	Ottawa Heart Institute Research Corporation
Conditions	Inflammation, Community Acquired Pneumonia (CAP), Inflammation Plaque, Atherosclerotic
Enrollment	168 participants
Start Date	2026-04-08
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-06 (estimated)
Updated on ClinicalTrials.gov	2026-05-11